Product Information
SELZENTRY 150 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $28.0158 per EA under NDC 49702022318. Its NADAC has been published 662 times since Nov 28, 2013.
FDA first approved this application on Aug 6, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the maraviroc market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702022318
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
MARAVIROCApproval Type
New Drug (NDA)
FDA Application
NDA022128FDA Approved
8/6/2007
TE Code
AB
On Market Since
5/16/2011
Pharmacological Classes
Price Statistics
The NADAC for SELZENTRY 150 MG TABLET has been published 662 times since Nov 28, 2013, and over the history we have for it it has risen 60.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $28.0158 per EA |
|---|---|
| All-time high | $28.0158 (Sep 30, 2026) |
| All-time low | $17.3433 (Jan 22, 2014) |
| 52-week high | $28.0158 |
| 52-week low | $27.9136 |
| Median price | $25.0585 |
| Average price | $24.2824 |
| Largest weekly change | +7.9% (Feb 8, 2017) |
| Weeks tracked | 662 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the maraviroc market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
maraviroc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
CCR5 Co-receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SELZENTRY 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SELZENTRY 150 MG TABLET, manufactured by ViiV Healthcare Company, is $28.0158 per EA (NDC 49702022318), effective Sep 30, 2026.
How has the price of SELZENTRY 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for SELZENTRY 150 MG TABLET has risen 60.5%. It has been tracked across 662 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SELZENTRY 150 MG TABLET?
Since Nov 28, 2013, the NADAC for SELZENTRY 150 MG TABLET has ranged from a low of $17.3433 (Jan 22, 2014) to a high of $28.0158 (Sep 30, 2026), with a median of $25.0585 per EA.
Are there cheaper alternatives to SELZENTRY 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SELZENTRY 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SELZENTRY 150 MG TABLET?
SELZENTRY 150 MG TABLET (NDC 49702022318) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.